{
  "symbol": "LLY",
  "year": 2025,
  "Period": "Q2",
  "report_type": "Q10",
  "metrics": {
    "mdna_sentiment": -0.2732,
    "outlook_sentiment": 0.1439,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.179
  },
  "top_positive": [
    {
      "sent": "16 Fair Value of Investments The following table summarizes certain fair value information at March\u00a031, 2025 and December\u00a031, 2024 for investment assets measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments: Fair Value Measurements Using Carrying Amount Cost (1) Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Fair Value March 31, 2025 Cash equivalents (2) $ 1,290.1 $ 1,290.1 $ 1,277.4 $ 12.7 $ \u2014 $ 1,290.1 Short-term investments: U.S.",
      "score": 0.9853
    },
    {
      "sent": "16 Fair Value of Investments The following table summarizes certain fair value information at March\u00a031, 2025 and December\u00a031, 2024 for investment assets measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments: Fair Value Measurements Using Carrying Amount Cost (1) Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Fair Value March 31, 2025 Cash equivalents (2) $ 1,290.1 $ 1,290.1 $ 1,277.4 $ 12.7 $ \u2014 $ 1,290.1 Short-term investments: U.S.",
      "score": 0.9853
    },
    {
      "sent": "16 Fair Value of Investments The following table summarizes certain fair value information at March\u00a031, 2025 and December\u00a031, 2024 for investment assets measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments: Fair Value Measurements Using Carrying Amount Cost (1) Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Fair Value March 31, 2025 Cash equivalents (2) $ 1,290.1 $ 1,290.1 $ 1,277.4 $ 12.7 $ \u2014 $ 1,290.1 Short-term investments: U.S.",
      "score": 0.9853
    }
  ],
  "top_negative": [
    {
      "sent": "Due to a very restrictive market for litigation liability insurance, we are self-insured for litigation liability losses for all our currently and previously marketed products.",
      "score": -0.7845
    },
    {
      "sent": "Due to a very restrictive market for litigation liability insurance, we are self-insured for litigation liability losses for all our currently and previously marketed products.",
      "score": -0.7845
    },
    {
      "sent": "Due to a very restrictive market for litigation liability insurance, we are self-insured for litigation liability losses for all our currently and previously marketed products.",
      "score": -0.7845
    }
  ],
  "forward_snippets": [
    "The following include some but not all of the factors that could cause actual results or events to differ from those anticipated: \u2022 the significant costs and uncertainties in the pharmaceutical research and development process, including with respect to the timing and process of obtaining regulatory approvals; \u2022 the impact and uncertain outcome of acquisitions and business development transactions and related costs; \u2022 intense competition affecting our products, pipeline, or industry; \u2022 market uptake of launched products and indications; \u2022 continued pricing pressures and the impact of actions of governmental and private payers affecting pricing of, reimbursement for, and patient access to pharmaceuticals, or reporting obligations related thereto; \u2022 safety or efficacy concerns associated with our or competitive products; \u2022 dependence on relatively few products or product classes for a significant percentage of our total revenue and a consolidated supply chain; \u2022 the expiration of intellectual property protection for certain of our products and competition from generic and biosimilar products; \u2022 our ability to protect and enforce patents and other intellectual property and changes in patent law or regulations related to data package exclusivity; \u2022 information technology system inadequacies, inadequate controls or procedures, security breaches, or operating failures; \u2022 unauthorized access, disclosure, misappropriation, or compromise of confidential information or other data stored in our information technology systems, networks, and facilities, or those of third parties with whom we share our data and violations of data protection laws or regulations; \u2022 issues with product supply and regulatory approvals stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to our and third-party facilities; \u2022 reliance on third-party relationships and outsourcing arrangements; \u2022 the use of artificial intelligence or other emerging technologies in various facets of our operations, which may exacerbate competitive, regulatory, litigation, cybersecurity, and other risks; \u2022 the impact of global macroeconomic conditions, including uneven economic growth or downturns or uncertainty, trade and other global disputes and interruptions, including related to tariffs, trade protection measures, and similar restrictions, international tension, conflicts, regional dependencies, or other costs, uncertainties, and risks related to engaging in business globally; \u2022 fluctuations in foreign currency exchange rates, changes in interest rates, and inflation or deflation; \u2022 significant and sudden declines or volatility in the trading price of our common stock and market capitalization; \u2022 litigation, investigations, or other similar proceedings involving past, current, or future products or activities; \u2022 changes in tax law and regulation, tax rates, or events that differ from our assumptions related to tax positions; \u2022 regulatory changes and developments; \u2022 regulatory oversight and actions regarding our operations and products; \u2022 regulatory compliance problems or government investigations; \u2022 risks from the proliferation of counterfeit, misbranded, adulterated, or illegally compounded products; 3 \u2022 actual or perceived deviation from environmental-, social-, or governance-related requirements or expectations; \u2022 asset impairments and restructuring charges; and \u2022 changes in accounting and reporting standards.",
    "We intend to adopt this standard in our Annual Report on Form 10-K for the year ending December 31, 2025.",
    "We intend to adopt this standard in our Annual Report on Form 10-K for the year ending December 31, 2027.",
    "12 Note\u00a03: Acquisitions We engage in various forms of business development activities to enhance or refine our product pipeline, including acquisitions, collaborations, investments, and licensing arrangements.",
    "We intend to adopt this standard in our Annual Report on Form 10-K for the year ending December 31, 2025."
  ],
  "curated_text": "Symbol: LLY. Year: 2025. Period: Q2. ReportType: Q10. Section: Management Discussion and Analysis (MD&A). Key metrics include sentiment, forward outlook, and risk hedging.  Top positive sentences: 16 Fair Value of Investments The following table summarizes certain fair value information at March\u00a031, 2025 and December\u00a031, 2024 for investment assets measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments: Fair Value Measurements Using Carrying Amount Cost (1) Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Fair Value March 31, 2025 Cash equivalents (2) $ 1,290.1 $ 1,290.1 $ 1,277.4 $ 12.7 $ \u2014 $ 1,290.1 Short-term investments: U.S. 16 Fair Value of Investments The following table summarizes certain fair value information at March\u00a031, 2025 and December\u00a031, 2024 for investment assets measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments: Fair Value Measurements Using Carrying Amount Cost (1) Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Fair Value March 31, 2025 Cash equivalents (2) $ 1,290.1 $ 1,290.1 $ 1,277.4 $ 12.7 $ \u2014 $ 1,290.1 Short-term investments: U.S. 16 Fair Value of Investments The following table summarizes certain fair value information at March\u00a031, 2025 and December\u00a031, 2024 for investment assets measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments: Fair Value Measurements Using Carrying Amount Cost (1) Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Fair Value March 31, 2025 Cash equivalents (2) $ 1,290.1 $ 1,290.1 $ 1,277.4 $ 12.7 $ \u2014 $ 1,290.1 Short-term investments: U.S. Top negative sentences: Due to a very restrictive market for litigation liability insurance, we are self-insured for litigation liability losses for all our currently and previously marketed products. Due to a very restrictive market for litigation liability insurance, we are self-insured for litigation liability losses for all our currently and previously marketed products. Due to a very restrictive market for litigation liability insurance, we are self-insured for litigation liability losses for all our currently and previously marketed products. Forward-looking snippets: The following include some but not all of the factors that could cause actual results or events to differ from those anticipated: \u2022 the significant costs and uncertainties in the pharmaceutical research and development process, including with respect to the timing and process of obtaining regulatory approvals; \u2022 the impact and uncertain outcome of acquisitions and business development transactions and related costs; \u2022 intense competition affecting our products, pipeline, or industry; \u2022 market uptake of launched products and indications; \u2022 continued pricing pressures and the impact of actions of governmental and private payers affecting pricing of, reimbursement for, and patient access to pharmaceuticals, or reporting obligations related thereto; \u2022 safety or efficacy concerns associated with our or competitive products; \u2022 dependence on relatively few products or product classes for a significant percentage of our total revenue and a consolidated supply chain; \u2022 the expiration of intellectual property protection for certain of our products and competition from generic and biosimilar products; \u2022 our ability to protect and enforce patents and other intellectual property and changes in patent law or regulations related to data package exclusivity; \u2022 information technology system inadequacies, inadequate controls or procedures, security breaches, or operating failures; \u2022 unauthorized access, disclosure, misappropriation, or compromise of confidential information or other data stored in our information technology systems, networks, and facilities, or those of third parties with whom we share our data and violations of data protection laws or regulations; \u2022 issues with product supply and regulatory approvals stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, cyber-attacks, or regulatory actions related to our and third-party facilities; \u2022 reliance on third-party relationships and outsourcing arrangements; \u2022 the use of artificial intelligence or other emerging technologies in various facets of our operations, which may exacerbate competitive, regulatory, litigation, cybersecurity, and other risks; \u2022 the impact of global macroeconomic conditions, including uneven economic growth or downturns or uncertainty, trade and other global disputes and interruptions, including related to tariffs, trade protection measures, and similar restrictions, international tension, conflicts, regional dependencies, or other costs, uncertainties, and risks related to engaging in business globally; \u2022 fluctuations in foreign currency exchange rates, changes in interest rates, and inflation or deflation; \u2022 significant and sudden declines or volatility in the trading price of our common stock and market capitalization; \u2022 litigation, investigations, or other similar proceedings involving past, current, or future products or activities; \u2022 changes in tax law and regulation, tax rates, or events that differ from our assumptions related to tax positions; \u2022 regulatory changes and developments; \u2022 regulatory oversight and actions regarding our operations and products; \u2022 regulatory compliance problems or government investigations; \u2022 risks from the proliferation of counterfeit, misbranded, adulterated, or illegally compounded products; 3 \u2022 actual or perceived deviation from environmental-, social-, or governance-related requirements or expectations; \u2022 asset impairments and restructuring charges; and \u2022 changes in accounting and reporting standards. We intend to adopt this standard in our Annual Report on Form 10-K for the year ending December 31, 2025. We intend to adopt this standard in our Annual Report on Form 10-K for the year ending December 31, 2027. 12 Note\u00a03: Acquisitions We engage in various forms of business development activities to enhance or refine our product pipeline, including acquisitions, collaborations, investments, and licensing arrangements. We intend to adopt this standard in our Annual Report on Form 10-K for the year ending December 31, 2025."
}